June 30, 2025 | Client News, NASDAQ: EZFL, NASDAQ: HTCR, NASDAQ: LASE, NASDAQ: MIGI, NASDAQ: OKYO, NASDAQ: SPRC, NYSE American: NNVC
Hinson brings a proven track record of driving growth and innovation in sales organizations BOCA RATON, FL / ACCESS Newswire / June 30, 2025 / Greenlane Holdings, Inc. (“Greenlane” or the “Company”) (Nasdaq:GNLN), one of the premier global sellers of premium cannabis accessories, child-resistant packaging, and specialty vaporization products, today announced the appointment of Mike Hinson as the […]
June 27, 2025 | Client News, NASDAQ: EZFL, NASDAQ: HTCR, NASDAQ: LASE, NASDAQ: MIGI, NASDAQ: OKYO, NASDAQ: SPRC, NYSE American: NNVC
Reaffirms Commitment to Transparency; No Immediate Plans to Utilize ATM or Shelf Registrations Scottsdale, AZ, June 27, 2025 (GLOBE NEWSWIRE) — CISO Global (NASDAQ: CISO), a leader in AI-powered cybersecurity software and compliance services, announced it has filed the renewal of its S-3 shelf registration, reducing the total shelf from $300 million to $100 million. The […]
February 28, 2025 | Client News, NASDAQ: EZFL, NASDAQ: HTCR, NASDAQ: LASE, NASDAQ: MIGI, NASDAQ: OKYO, NASDAQ: SPRC, NYSE American: NNVC
TRNR details $50M pro forma annual revenue guidance, rationale of expected Sportstech acquisition, comments on market manipulation concerns and bitcoin as a Treasury asset AUSTIN, TX / ACCESS Newswire / February 27, 2025 / Interactive Strength Inc. (Nasdaq:TRNR) (“TRNR” or the “Company”), maker of innovative specialty fitness equipment under the CLMBR and FORME brands, today […]
May 8, 2024 | Client News, NASDAQ: OKYO
LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA […]
April 30, 2024 | Client News, NASDAQ: OKYO
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA […]
April 9, 2024 | Client News, NASDAQ: OKYO
LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA […]
April 2, 2024 | Client News, NASDAQ: OKYO
LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA […]
